tiprankstipranks
Blurbs

Robert W. Baird Remains a Buy on Syneos Health (SYNH)

In a report issued on July 7, Eric Coldwell from Robert W. Baird maintained a Buy rating on Syneos Health (SYNHResearch Report), with a price target of $99.00. The company’s shares closed last Wednesday at $71.24.

According to TipRanks.com, Coldwell is a 5-star analyst with an average return of 7.7% and a 50.0% success rate. Coldwell covers the Healthcare sector, focusing on stocks such as Quest Diagnostics, AmerisourceBergen, and Cardinal Health.

Syneos Health has an analyst consensus of Strong Buy, with a price target consensus of $89.00, a 28.9% upside from current levels. In a report released yesterday, Barclays also maintained a Buy rating on the stock with a $90.00 price target.

See today’s best-performing stocks on TipRanks >>

Syneos Health’s market cap is currently $7.31B and has a P/E ratio of 30.82.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Syneos Health, Inc. provides outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded on August 13, 2010 and is headquartered in Morrisville, NC.

Read More on SYNH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More